Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Melanoma 1Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Gemcitabine 24Cisplatin 18Carboplatin 10Paclitaxel 9Specimen Handling 6Nivolumab 6Doxorubicin 6Docetaxel 6pembrolizumab 5Magnetic Resonance Spectroscopy 5cabozantinib 4avelumab 4Vinblastine 4Radiotherapy 4Methotrexate 4Fluorouracil 4enfortumab vedotin 3atezolizumab 3aflibercept 3Trastuzumab 3Sunitinib 3Ramucirumab 3Platinum 3Ipilimumab 3CTLA-4 Antigen 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3vinflunine 2pegfilgrastim 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urethral Neoplasms × Interleukin-7 × Genitourinary × Clear all
NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡